Page 33 - MI-1-2

Microbes & Immunity Homologous versus heterologous COVID-19 vaccines

immune sera elicited by vaccines after boost. Emerg Microbes nCoV-19 and BNT162b2 prime-boost vaccination elicits
Infect. 2022;11:337-343. potent neutralizing antibody responses and T cell reactivity
against prevalent SARS-CoV-2 variants. EBioMedicine.
doi: 10.1080/22221751.2021.2022440
2022;75:103761.
7. Atmar RL, Lyke KE, Deming ME, et al. Homologous and
heterologous Covid-19 booster vaccinations. N Engl J Med. doi: 10.1016/j.ebiom.2021.103761
2022;386:1046-1057. 17. Hillus D, Schwarz T, Tober-Lau P, et al. Safety, reactogenicity,
and immunogenicity of homologous and heterologous
doi: 10.1056/NEJMoa2116414
prime-boost immunisation with ChAdOx1 nCoV-19 and
8. Barros-Martins J, Hammerschmidt SI, Cossmann A, BNT162b2: A prospective cohort study. Lancet Respir Med.
et al. Immune responses against SARS-CoV-2 variants 2021;9:1255-1265.
after heterologous and homologous ChAdOx1 nCoV-19/
BNT162b2 vaccination. Nat Med. 2021;27:1525-1529. doi: 10.1016/S2213-2600(21)00357-X
18. Kant R, Dwivedi G, Zaman K, et al. Immunogenicity and
doi: 10.1038/s41591-021-01449-9
safety of a heterologous prime-boost COVID-19 vaccine
9. Behrens GM, Cossmann A, Stankov MV, et al. SARS-CoV-2 schedule: ChAdOx1 vaccine Covishield followed by BBV152
delta variant neutralisation after heterologous ChAdOx1-S/ Covaxin. J Travel Med. 2021;28:taab166.
BNT162b2 vaccination. Lancet. 2021;398:1041-1042.
doi: 10.1093/jtm/taab166
doi: 10.1016/S0140-6736(21)01891-2
19. Khong KW, Liu D, Leung KY, et al. Antibody response of
10. Benning L, Tollner M, Hidmark A, et al. Heterologous combination of BNT162b2 and coronavac platforms of
ChAdOx1 nCoV-19/BNT162b2 prime-boost vaccination COVID-19 vaccines against Omicron variant. Vaccines
induces strong humoral responses among health care (Basel). 2022;10:160.
workers. Vaccines (Basel). 2021;9:857.
doi: 10.3390/vaccines10020160
doi: 10.3390/vaccines9080857
20. Khoo NKH, Lim JME, Gill US, et al. Differential
11. Borobia AM, Carcas AJ, Perez-Olmeda M, et al. immunogenicity of homologous versus heterologous boost
Immunogenicity and reactogenicity of BNT162b2 booster in Ad26.COV2.S vaccine recipients. Med. 2022;3:104-118.e4.
in ChAdOx1-S-primed participants (CombiVacS):
A multicentre, open-label, randomised, controlled, phase 2 doi: 10.1016/j.medj.2021.12.004
trial. Lancet. 2021;398:121-130. 21. Li J, Hou L, Guo X, et al. Heterologous AD5-nCOV plus
CoronaVac versus homologous CoronaVac vaccination:
doi: 10.1016/S0140-6736(21)01420-3
A randomized phase 4 trial. Nat Med. 2022;28:401-419.
12. Clemens SAC, Folegatti PM, Emary KRW, et al. Efficacy doi: 10.1038/s41591-021-01677-z
of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-
CoV-2 lineages circulating in Brazil. Nat Commun. 22. Liu X, Shaw RH, Stuart ASV, et al. Safety and immunogenicity
2021;12:5861. of heterologous versus homologous prime-boost schedules
with an adenoviral vectored and mRNA COVID-19 vaccine
doi: 10.1038/s41467-021-25982-w
(Com-COV): A single-blind, randomised, non-inferiority
13. Firinu D, Perra A, Campagna M, et al. Evaluation of trial. Lancet. 2021;398:856-869.
antibody response to heterologous prime-boost vaccination
with ChAdOx1 nCoV-19 and BNT162b2: An observational doi: 10.1016/S0140-6736(21)01694-9
study. Vaccines (Basel). 2021;9:1478. 23. Moghnieh R, Mekdashi R, El-Hassan S, et al. Immunogenicity
and reactogenicity of BNT162b2 booster in BBIBP-
doi: 10.3390/vaccines9121478
CorV-vaccinated individuals compared with homologous
14. Glockner S, Hornung F, Baier M, et al. Robust neutralizing BNT162b2 vaccination: Results of a pilot prospective cohort
antibody levels detected after either SARS-CoV-2 vaccination study from Lebanon. Vaccine. 2021;39:6713-6719.
or one year after infection. Viruses. 2021;13:2003.
doi: 10.1016/j.vaccine.2021.10.007
doi: 10.3390/v13102003
24. Munro APS, Janani L, Cornelius V, et al. Safety and
15. Gram MA, Nielsen J, Schelde AB, et al. Vaccine effectiveness immunogenicity of seven COVID-19 vaccines as a third
against SARS-CoV-2 infection, hospitalization, and death dose (booster) following two doses of ChAdOx1 nCov-19
when combining a first dose ChAdOx1 vaccine with a or BNT162b2 in the UK (COV-BOOST): A blinded,
subsequent mRNA vaccine in Denmark: A nationwide multicentre, randomised, controlled, phase 2 trial. Lancet.
population-based cohort study. PLoS Med. 2021;18:e1003874. 2021;398:2258-2276.
doi: 10.1371/journal.pmed.1003874 doi: 10.1016/S0140-6736(21)02717-3
16. Gross R, Zanoni M, Seidel A, et al. Heterologous ChAdOx1 25. Normark J, Vikstrom L, Gwon YD, et al. Heterologous

Volume 1 Issue 2 (2024) 27 doi: 10.36922/mi.3757